Tackling multiple sclerosis.
Wekerle
Hartmut
H
D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects; D000069059:Atorvastatin; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D006538:Heptanoic Acids; D000949:Histocompatibility Antigens Class II; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin